ArriVent Launches with Up To $150M in Series A Financing and Strategic Licensing Agreement for Clinical-Stage Oncology Asset

Arrivent Biopharma

related news
ADARx Pharmaceuticals raises 4.463 million in upsized US IPO

Reuters

September 25 2026
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy

NASDAQ

July 14 2026

Get In Touch

Contact Us